A pharmacist by training, Dr. Nicolas Bertrand is an assistant professor at Laval University’s School of Pharmaceutical Studies. He is also a researcher in the department of Endocrinology and Nephrology at the CHU de Quebec Research Center. His research in nanomedicine focuses on potentiating the efficacy of therapeutic molecules by using nanotechnologies. He is the editor of the European Journal of Pharmaceutics and Biopharmaceutics (Elsevier, IF: 4.2) and director of the « Biopharmacy et pharmacometrics » strategic cluster of the Réseau Québécois de Recherche sur les Médicaments (rqrm.ca). He is an associate member of the Institute on Nutraceuticals and Functional Foods (INAF) and of the Centre de Recherche sur les Matériaux Avancés (CERMA).

Encapsulating bioactive molecules through differentiated technologies

Many drugs in development, or already on the market, possess suboptimal physiochemical or pharmacological characteristics. Nanomedicine can harness the unique features of nanomaterials to facilitate the administration of these drugs, or potentiate their efficacy. Encapsulation of bioactive molecules in nanoparticles can prevent their metabolism, ameliorate their pharmacokinetics, or ensure their optimal distribution to diseased tissues. Altogether, these effects can pave the way for more efficient and better tolerated drugs.

Dr. Nicolas Bertrand’s laboratory uses functional polymers and lipids to encapsulate a variety of bioactive molecules in clinically-relevant drug delivery vehicles.

Elucidate the interactions of nanomaterials with the immune system

Like other drugs, the use of nanoparticles as drug delivery vehicles can trigger unexpected or undesirable reactions. The type of system, its size, or the materials used in its preparation can all influence the nature and extent of its interactions with the immune system. The development of better tolerated nanomedicines necessitates a better understanding of how drug delivery platforms interact with the various components of the immune system.

Through a unique expertise in the preparation of nanoparticle libraries, combined with an established knowledge in preclinical pharmacokinetics, Dr. Nicolas Bertrand’s laboratory specialises in studying the fate of nano- and biomaterials in living animals. This approach leads to an integrated understanding of the interactions of materials with complete, functional biological systems.

2705, boulevard Laurier
Québec, Québec
Canada G1V 4G2
31 entries « 1 of 4 »

Chotard E, Mohammadi F, Julien P, Berthiaume L, Rudkowska I, Bertrand N

Drinkable lecithin nanovesicles to study the biological effects of individual hydrophobic macronutrients and food preferences.

Journal Article

Food Chem, 322 , pp. 126736, 2020, ISSN: 0308-8146.

Abstract | Links:

Dikpati A, Mohammadi F, Greffard K, Queant C, Arnaud P, Bastiat G, Rudkowska I, Bertrand N

Residual Solvents in Nanomedicine and Lipid-Based Drug Delivery Systems: a Case Study to Better Understand Processes.

Journal Article

Pharm Res, 37 (8), pp. 149, 2020, ISSN: 0724-8741.

Abstract | Links:

Perreault M, Maltais R, Roy J, Picard S, Popa I, Bertrand N, Poirier D

Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model.

Journal Article

Invest New Drugs, 37 (3), pp. 431-440, 2019, ISSN: 0167-6997.

Abstract | Links:

O'Connor S, Chaouch IR, Rudkowska I, Bertrand N

Nanotechnologies dans le domaine agroalimentaire : que devons-nous savoir 

Journal Article

Nutr sci évol, 16 , pp. 9-15, 2019, ISSN: 1708-0452.

Grenier P, de Oliveira Viana IM, Lima EM, Bertrand N

Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo.

Journal Article

J Control Release, 287 , pp. 121-131, 2018, ISSN: 0168-3659.

Abstract | Links:

Ouellette M, Masse F, Lefebvre-Demers M, Maestracci Q, Grenier P, Millar R, Bertrand N, Prieto M, Boisselier E

Insights into gold nanoparticles as a mucoadhesive system.

Journal Article

Sci Rep, 8 (1), pp. 14357, 2018, ISSN: 2045-2322.

Abstract | Links:

Bisso PW, Tai M, Katepalli H, Bertrand N, Blankschtein D, Langer R

Molecular Rotors for Universal Quantitation of Nanoscale Hydrophobic Interfaces in Microplate Format.

Journal Article

Nano Lett, 18 (1), pp. 618-628, 2018, ISSN: 1530-6984.

Abstract | Links:

Maltais R, Trottier A, Roy J, Ayan D, Bertrand N, Poirier D

Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments.

Journal Article

J Steroid Biochem Mol Biol, 178 , pp. 167-176, 2018, ISSN: 0960-0760.

Abstract | Links:

Bertrand N, Grenier P, Mahmoudi M, Lima EM, Appel EA, Dormont F, Lim JM, Karnik R, Langer R, Farokhzad OC

Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics.

Journal Article

Nat Commun, 8 (1), pp. 777, 2017, ISSN: 2041-1723.

Abstract | Links:

Chapeau AL, Bertrand N, Briard-Bion V, Ramon P, Poncelet D, Bouhallab S

Coacervates of whey proteins to protect and improve the oral delivery of a bioactive molecule

Journal Article

J Funct Foods, 38 , pp. 197-204, 2017, ISSN: 1756-4646.

| Links:

31 entries « 1 of 4 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche sur les matériaux avancés, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2025-04-30
  • Designing quality control strategies to assess the self-assembly and biological stability of chitosan nanoparticles, Partenariat, MITACS Inc., Accélération Québec (MITACS et gouvernement provincial), from 2018-05-01 to 2021-06-30
  • Engineering functional nanoparticles using libraries of polymers, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2016-04-01 to 2021-03-31
  • Envisager une protection contre le passage des perturbateurs endocriniens à travers la peau, Subvention, Fondation de l'Université Laval, from 2019-02-01 to 2020-12-31
  • Nanopharmacologie et nanomédecine : vers le développement de plates-formes technologiques pour la vectorisation des médicaments, Subvention, Fonds de recherche du Québec - Santé, Établissement de jeunes chercheurs - Juniors 1, from 2018-07-01 to 2022-06-30
  • Nanopharmacologie et nanomédecine: vers le développement de plates-formes technologiques pour la vectorisation des médicaments, Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2018-07-01 to 2022-06-30
  • Prevention of glioblastoma recurrence by injection in the resection cavity of a hydrogel formed by targeted lipid nanocapsules loaded with anticancer drugs, GLIOGEL, Subvention, Fonds de recherche du Québec - Santé, ERA-NET EuroNanoMed, from 2018-04-01 to 2021-03-31

Recently finished projects

  • Évaluation de l'impact de nanoparticules liposomales sur l'efficacité in vivo du transport intracellulaire de protéines vectorisées par la plateforme Feldan Shuttle, Partenariat, Ministère de l'Économie et de l'Innovation, Programme de soutien aux organismes de recherche et d’innovation (PSO) - Volet 1 : Soutien au fonctionnement d'organisme (Ancien PSVT), from 2018-10-22 to 2019-10-21
  • Financement pour la formation d'une étudiante au doctorat, Subvention, Fondation du CHU de Québec, from 2019-06-17 to 2020-03-31
  • Interactions non-covalentes pour l'isolation des nanoparticules, Subvention, Fonds de recherche du Québec - Nature et technologies, Établissement de la relève professorale, from 2018-04-01 to 2020-03-31
  • Profil toxicologique de nanosphères de silice comme vecteur pharmaceutique, Partenariat, Ministère de l'Économie et de l'Innovation, Programme de soutien aux organismes de recherche et d’innovation (PSO) - Recherche-innovation - Volet 2a, from 2019-10-01 to 2020-03-31
Data provided by the Université Laval research projects registery